-

11:57:46 PM

Latest ABBV Stock Market News

ABBV - Abbvie Inc

09/16/21 8:00 AM

NYSE : ABBV

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie (NYSE: ABBV) today announced that it has submitted applications seeking approval for upadacitinib (15 mg and 30 mg (maintenance dose) and 45 mg (induction dose)) for the treatment of adults with moderately to severely active ulcerative

RHEA-AI

neutral

09/13/21 6:30 AM

NYSE, Nasdaq : ABBV, RGNX

AbbVie and REGENXBIO Announce Eye Care Collaboration

AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD),

RHEA-AI

neutral

09/10/21 10:27 AM

NYSE : ABBV

dividends

AbbVie Declares Quarterly Dividend

The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.30 per share.The cash dividend is payable November 15, 2021 to stockholders of record at the close of business on October 15, 2021.Since the

RHEA-AI

neutral

09/10/21 9:00 AM

NYSE : ABBV

AbbVie to Highlight Its Leadership in Movement Disorders at the International Parkinson and Movement Disorder Society Virtual Congress 2021

AbbVie (NYSE: ABBV) today announced that data from its robust neuroscience portfolio will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress 2021, taking place September 17-22. More than 20 abstracts

RHEA-AI

neutral

09/09/21 8:00 AM

NYSE : ABBV

conferences

AbbVie to Present at the Morgan Stanley Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on Wednesday, September 15, 2021. Richard A. Gonzalez, chairman and chief executive officer, Michael Severino, M.D., vice chairman and

RHEA-AI

neutral

09/09/21 7:00 AM

NYSE, Nasdaq : ABBV, GMAB

clinical trial

Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet

AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced The Lancet published the results of the dose escalation part of the Phase 1/2 EPCORE™ NHL-1 first-in-human (FIH) dose escalation and cohort expansion

RHEA-AI

neutral

09/09/21 7:00 AM

Nasdaq, NYSE : GMAB, ABBV

clinical trial

Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet

Phase 1/ 2 first-in-human dose escalation and cohort expansion trial evaluating safety and preliminary efficacy of epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin’ s lymphoma published in The Lancet Results also presented during oral session at the 16 th Annual International Conference on Malignant Lymphoma and as a poster at the...

RHEA-AI

neutral

09/08/21 9:10 AM

NYSE : ABBV

conferences

AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress

AbbVie (NYSE: ABBV) today announced that data from its migraine portfolio will be presented at the International Headache Congress 2021, held jointly this year by the International Headache Society and the European Headache Federation, from

RHEA-AI

neutral

08/24/21 8:00 AM

NYSE : ABBV

European Commission Approves RINVOQ® (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis

AbbVie (NYSE: ABBV) today announced the European Commission (EC) approved RINVOQ ® (upadacitinib), an oral, selective and reversible JAK inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and

RHEA-AI

neutral

08/18/21 5:28 PM

NYSE : ABBV

New England Journal of Medicine Publishes 12-Week Results from Study Evaluating Atogepant for the Preventive Treatment of Migraine

AbbVie (NYSE: ABBV) today announced that the New England Journal of Medicine ( NEJM) has published 12-week results from the Phase 3 ADVANCE trial evaluating atogepant for the preventive treatment of migraine in adults who meet criteria for episodic

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

ABBV Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.abbvie.com
CeoRichard Gonzalez
Security nameAbbvie Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees2020
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address1 N Waukegan Rd
StateIllinois
CityNorth Chicago
Zip60064-1802
CountryUS
Phone18479327900

ABBV Description:

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The Company strives to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.